T-DM1 ± Pertuzumab als First-line-Option in der Phase-III-Prüfung: MARIANNE-Studie beim HER2-positiven Mammakarzinom

Publisher： Karger

E-ISSN： 2296-5262|33|10|559-559

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.10, 2010-09, pp. : 559-559

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 139, Iss. 10, 2016-11 ,pp. : 2336-2342

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

By Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 405-414

Informa Healthcare

Access to resources Recommend Favorite

T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 3, 2017-11 ,pp. : 216-222

Bentham Science Publishers

Access to resources Recommend Favorite

HER2-Diagnostik: Standard und zukünftige Entwicklungen / Neuere Therapiekonzepte beim metastasierten Mammakarzinom / Therapieentscheidung – Einfluss durch Patienten?

By  

Oncology Research and Treatment, Vol. 25, Iss. 5, 2004-11 ,pp. : 1-28

Karger

Access to resources Recommend Favorite

Grenzen der Sentinel-Lymphknotenbiopsie beim Mammakarzinom

By  

Gynäkologisch-geburtshilfliche Rundschau, Vol. 45, Iss. 3, 2005-06 ,pp. : 127-131

Karger

Access to resources Recommend Favorite